media – Page 7 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

The king of cancer is to be defeated

Pancreatic cancer is known as the “king of cancer” because of its high malignancy and lack of effective drug treatment. However, the research and development community has never stopped its efforts to conquer this type of cancer. Recently, Hengrui Medicine announced that the results of the Phase III study of irinotecan liposome (II) combined with advanced pancreatic cancer were published in the Nature sub-journal “Signal Transduction and Targeted Therapy”. The results showed that the irinotecan liposome combination regimen reduced the risk of death in pancreatic cancer patients by 37% compared with the control group. In the next era beyond chemotherapy, perhaps ADC drugs will become the main force in the fight against pancreatic cancer. For example, Innovent Biologics’ ADC targeting cluadin18.2 and Lepu Bio’s ADC targeting EGFR each have their own surprises, and both have shown breakthrough efficacy in the remission rate of pancreatic cancer. In addition, Kangfang has also ...
- Source: drugdu
- 45
- November 12, 2024
FIME

Organiser：Informa Markets Time： June 11 – 13, 2025 Address：1901 Convention Center Drive, Miami Beach, USA Exhibition hall：Miami Beach Convention Center Product range: Medical Equipment: Laboratory supplies, operating room equipment, medical consumables, orthopedic products, medical imaging equipment, ophthalmic equipment, therapeutic instruments and accessories, biochemical and testing equipment, diagnostic analyzers and accessories, electronic medical instruments, medical furniture. Rehabilitation & Nursing: Assistive devices for disabled individuals, rehabilitation nursing equipment, monitoring instruments, orthopedic surgical equipment, dental equipment, cleaning, disinfection, and sterilization products, medical packaging, home care products, needles and cotton goods, pharmaceuticals, nutritional, and healthcare products, disposable products, etc. About FIME： The Florida International Medical Expo (FIME) in Miami, USA, is the largest medical professional exhibition in the southeastern United States. Besides exhibiting companies and professional buyers primarily from Florida, it attracts numerous exhibitors and buyers from Latin American countries. A vast amount of products and equipment are transshipped through Florida to neighboring ...
- Source: drugdu
- 43
- November 12, 2024
【EXPERT Q&A】What is a Certificate of Free Sale of medical Devices?

Drugdu.com expert’s response: Medical Device Free Sale Certificate (FSC): Definitions, Roles, Differences from Registration Certificates, and Application Process Ⅰ. Definition A Medical Device Free Sale Certificate (FSC) is a document issued by the competent authority or certification body in the country or region where the medical device manufacturer or supplier is located. It serves as proof that a specific medical device is legally and freely sold in its country of origin or region, and complies with the corresponding regulations and standards. Ⅱ. Roles Proof of Compliance: This certificate demonstrates that the medical device has passed the review and approval of the regulatory agency in the country of origin or region, and complies with local regulations and standards. Support for International Trade: The Medical Device Free Sale Certificate is often used to support international trade in medical devices, especially when entering certain countries or regional markets, proving that the product meets ...
- Source: drugdu
- 49
- November 11, 2024
Domestic bispecific antibodies win another victory

Recently, Wellizbo announced that its independently developed and globally intellectual property-owned Class 1 new drug LBL-034 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma (MM). LBL-034 is a new generation of humanized bispecific T cell engaging antibodies targeting GPRC5D and CD3 developed using Wellizbo’s independently developed and intellectual property-owned CD3 bispecific antibody technology platform “LeadsBodyTM”. It is the third CD3 T cell connector targeting GPRC5D to enter the clinical stage in the world. Multiple myeloma (MM) is a malignant plasma cell disease caused by abnormal proliferation of clonal plasma cells, accounting for about 10% of hematological malignancies and about 1% of all tumor diseases. MM is still an incurable malignancy. With multiple lines of medication, the interval between relapses will become shorter and shorter, and eventually evolve into RRMM, which seriously threatens the life and health of patients. ...
- Source: drugdu
- 50
- November 11, 2024
Five questions and answers about the application of drug traceability codes in medical insurance

Recently, the National Medical Insurance Administration has attracted attention through the verification of drug traceability codes. What is a drug traceability code? What does it mean if a drug traceability code is scanned repeatedly? What role does the drug traceability code play in ensuring the security of medical insurance funds? How to use drug traceability codes? What is a drug traceability code? Answer: The drug traceability code is the “electronic ID card” of the drug. It is usually composed of a series of numbers, letters and (or) symbols. It is marked in a prominent position on the drug packaging box. It is the unique identity label given to each box of drugs from the time of production. If the drug traceability code appears repeatedly during the circulation process, the drug may be a “returned drug”, a counterfeit drug, or sold in a scrambled manner. The drug traceability code has three ...
- Source: drugdu
- 45
- November 11, 2024
Pharma’s capital operation era

On October 31, CSPC Pharmaceutical Group issued a third-quarter profit warning announcement. It is expected that the company’s net profit in the first three quarters of this year will decrease by about 16% year-on-year from 4.495 billion yuan in the same period last year. In total, CSPC Pharmaceutical Group’s net profit in the first three quarters of this year is about 3.776 billion yuan. According to the interim report, CSPC Pharmaceutical Group’s revenue in the first half of the year was 16.284 billion yuan, a year-on-year increase of 1.27%, and its net profit was 3.02 billion, a year-on-year increase of 1.8%. According to this calculation, the net profit in the third quarter was only 760 million yuan, while the same period last year, this figure was 1.528 billion yuan. In other words, the net profit in the third quarter of this year was halved, a year-on-year decrease of 50%. As ...
- Source: drugdu
- 44
- November 11, 2024
A biotech company was deregistered and liquidated

Recently, Asia Pacific Pharmaceuticals issued the “Announcement on the Progress of Liquidation and Cancellation of Joint Ventures”. A Biotech company that it established with an investment of approximately RMB 35.84 million in 2019 has completed the deregistration procedures. Asia Pacific Pharmaceuticals is mainly engaged in pharmaceutical manufacturing and CRO service businesses, covering chemical pharmaceutical preparations, chemical APIs, and pharmaceutical research and development. Its main products include roxithromycin capsules, cephalexin capsules, azithromycin dispersible tablets, and azithromycin for injection. The Biotech business area that was deregistered and liquidated this time was the new track that Asia Pacific Pharmaceuticals first contacted at the time – industrial hemp. It is reported that according to the different mass concentrations of tetrahydrocannabinol (THC) contained in hemp, hemp can be divided into industrial hemp, intermediate hemp, and recreational hemp. Industrial hemp refers to hemp with a THC content of less than 0.3%, which does not show psychoactive ...
- Source: drugdu
- 46
- November 11, 2024
Invest 7.5 billion yuan in 5 years! Pfizer increases investment in innovative drug research and development in China

Disclaimer: Due to limited proficiency, errors are inevitable, or some information may not be timely. Please feel free to leave a message to indicate. This article only provides an introduction to medical and health-related drugs, and does not recommend treatment plans (if applicable); This article does not constitute any investment advice. On the morning of November 6th, at the 7th China International Import Expo (CIIE), Jean Christophe Pointeau, President of Pfizer China, a multinational pharmaceutical giant, revealed that the company will launch the “Pfizer China 2030 Strategy” during this year’s CIIE. From 2025 to 2030, Pfizer will invest 1 billion US dollars, about 7.5 billion yuan, in China. Pfizer will continue to invest in accelerating innovation, improving diagnostic capabilities and treatment standards, and promoting the development of the local biotechnology industry to support the ‘Healthy China 2030’ initiative. This strategy is based on three pillars: firstly, accelerating the launch of ...
- Source: drugdu
- 79
- November 9, 2024
Domestic dual antibody makes another breakthrough

Introduction: Has the best potential in its class Recently, Weili Zhibo announced that its independently developed Class 1 new drug LBL-034, which has global intellectual property rights, has been granted orphan drug status by the US Food and Drug Administration (FDA) for the treatment of multiple myeloma (MM). LBL-034 is a new generation of humanized bispecific T cell linker antibody targeting GPRC5D and CD3, developed using LeadsBody TM, a CD3 bispecific technology platform independently developed by Weili Libo with intellectual property rights. It is the third CD3 T cell linker targeting GPRC5D to enter the clinical stage worldwide. Figure 1: GPRC5D/CD3 dual antibody under global research Image source: Pharmaceutical Intelligence Data Multiple myeloma (MM) is a malignant plasma cell disease caused by abnormal proliferation of clonal plasma cells, accounting for approximately 10% of hematological malignancies and 1% of all tumor diseases. MM is still an incurable malignant tumor. With ...
- Source: drugdu
- 58
- November 9, 2024
Johnson&Johnson Global Vice President Resigns

After optimizing the overall structure of Ziqiang Sheng, personnel change messages often occur. Recently, Larry Jones, Global Vice President of Medical Technology and Group Chief Information Officer at Johnson&Johnson, announced his decision to resign. He will retire from Johnson&Johnson Medical Devices, and details such as when he will officially resign or who will take over are still unknown. 35 year veteran resigns, Johnson&Johnson personnel changes frequently Larry Jones is an experienced veteran at Johnson&Johnson Medical, having served for 35 years. During his tenure at Johnson&Johnson’s Medical Devices division, Larry Jones was particularly dedicated to driving innovation in the fields of oncology, orthopedics, cardiovascular and general surgery, and revolutionizing digital surgical connectivity solutions through advanced technologies such as surgical robots and machine learning platforms. Larry Jones has served as the trans regional global CIO of Janssen Pharmaceuticals for more than six years. He is the executive member of the Johnson African ...
- Source: drugdu
- 67
- November 9, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.